TrialX
Advanced Filters
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
noise

Found 3,739 clinical trials

r ref3

ctgov trial 2

    dddd

18 years and younger Male
T Trial Transparency email recommended (Toll free number for US & Canada)

Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

Primary Objective: To evaluate the efficacy of dupilumab in patients with persistent asthma Secondary Objectives: To evaluate the safety and tolerability of dupilumab To evaluate the effect of dupilumab on improving patient reported outcomes including health related quality of life To evaluate dupilumab systemic exposure and immunogenicity

12 years and older All Phase 3
T Trial Transparency email recommended (Toll free number for US & Canada)

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

18 years and older All Phase 1
T Trial Transparency email recommended (Toll free number for US & Canada)

Safety Pharmacokinetics and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

Primary Objectives: Phase 1: To characterize the safety and tolerability of isatuximab in kidney transplant candidates. Phase 2: To evaluate the efficacy of isatuximab in desensitization of patients awaiting kidney transplantation. Secondary Objectives: Phase 2: To characterize the safety profile of isatuximab in kidney transplant candidates. To characterize the pharmacokinetic …

18-70 years All Phase 1/2
T Trial Transparency email recommended (Toll free number for US & Canada)

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

18 years and older All Phase 1
t test

Formal Build 2 V4.1

1 years and older Male Phase N/A
t ts

New Test Study

100 years and younger Female Phase N/A
w wew

sdsc

cew

100 years and younger Female Phase N/A
q qa

QA_Study Trial 01

Test Comment here

100 years and younger All Phase N/A
M Mor Nahum, PhD

testslug trial title

Major depressive disorder (MDD) is a common, recurrent, and frequent chronic disorder. Treatment is often challenging; up to 40% of patients do not benefit sufficiently from existing antidepressant interventions including trials of medication and psychotherapy. Up to 25% of patients manifest a chronic course of illness, resulting in a need …

18-65 years All Phase N/A

Simplify language using AI